Safety and efficacy of complement factor H (CFH) inhibitor GT103 in advanced non-small cell lung cancer (NSCLC): Results of a phase Ib first in human dose escalation study.

Hirva Mamdani, Edward F. Patz, Andrew B. Nixon et al.|Journal of Clinical Oncology|2024

Cited by 2